Beneficial effects of CHF6467, a modified human nerve growth factor, in experimental neonatal hypoxic–ischaemic encephalopathy
CHF6467 administered intranasally is a promising therapy, in combination with TH, for the treatment of HIE.
Authors
- Amira Saidi (ORCID: https://orcid.org/0000-0002-9716-9624)
- Walter Balduini (ORCID: https://orcid.org/0000-0001-8438-9559)
- Laura Tigli
- Elisa Landucci (ORCID: https://orcid.org/0000-0002-6776-2857)
- Elisa Schiavi
- Silvia Carloni (ORCID: https://orcid.org/0000-0003-3634-3454)
- Bruno Pietro Imbimbo (ORCID: https://orcid.org/0000-0002-0327-7262)
- Costanza Mazzantini (ORCID: https://orcid.org/0000-0003-1842-1332)
- Domenico E. Pellegrini‐Giampietro (ORCID: https://orcid.org/0000-0002-3920-2297)
- Fabrizio Facchinetti
- Barbara Pioselli
- Dalila Mango
Institutions
- University of Rome Tor Vergata (IT)
- University of Urbino (IT)
- European Brain Research Institute (IT)
- Chiesi (Italy) (IT)
- University of Florence (IT)
Publication Details
- Journal
- British Journal of Pharmacology
- Published
- 2024-10-08
- DOI
- https://doi.org/10.1111/bph.17353
- Citations
- 6
- Primary Topic
- Neonatal and fetal brain pathology
- Type
- article
- Field-Weighted Citation Impact
- 6.66